A Phase 3 interventional study of Netarsudil/Latanoprost 0.02%/0.005% and GANFORT® in Open Angle Glaucoma and Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 68 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-31.
Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Glaucoma, Open-Angle by Alcon — 1 open to participants now, 1 under way, none of them phase 3. Glaucoma, Open-Angle · Alcon.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 21st largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2017, is one of 43 in phase 3, and was the 116th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →1 of the 126 studies in Glaucoma, Open-Angle by Alcon is open now, in 1 country. Recruiting first, the newest first:
Alcon Research · Sites in United States
Ages 45+
By country, each count listing its studies:
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 37 · Phase 3 45 · Phase 4 31
First in 1999; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 436 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 154 across the 112 interventional studies, 88 across the 5 observational. Of the 121 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Aerie Pharmaceuticals, one of the names counted as Alcon. Under that name alone:
Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is intended to test the effectiveness and safety of Netarsudil / Latanoprost 0.02% / 0.005% Ophthalmic Solution, relative to GANFORT® for lowering of intraocular pressure (IOP) in patients with elevated intraocular pressure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ophthalmic:
Any abnormality preventing reliable Goldmann applanation tonometry of either eye (e.g., keratoconus).
Systemic:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PG324 Ophthalmic Solution (netarsudil 0.02% / latanoprost 0.005%) one drop daily to each eye for 180 days.
Drug: Netarsudil/Latanoprost 0.02%/0.005%
GANFORT® (bimatoprost 0.03%/timolol 0.5%) Ophthalmic solution one drop daily to each eye for 180 days.
Drug: GANFORT®
Topical sterile ophthalmic solution
Topical sterile ophthalmic solution
Mean Diurnal Intraocular Pressure by Goldmann Applanation Tonometry
Comparison of PG324 to Ganfort for mean intraocular pressure at specified timepoints at Week 2, Week 6 and Month 3.
Time frame: Day 90
Recruitment took place in 11 European countries between September 2017 and May 2020.
| Milestone | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® |
|---|---|---|
| Started | 218 | 212 |
| Intent-to-treat population | 218 | 212 |
| Per-protocol population | 169 | 170 |
| Safety population | 218 | 212 |
| Completed | 163 | 199 |
| Not completed | 55 | 13 |
| Withdrew: Adverse event | 40 | 4 |
| Withdrew: Withdrawal by subject | 5 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Disallowed concurrent medication | 1 | 1 |
| Withdrew: Protocol violation | 3 | 3 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Other - reason not reported in csr | 4 | 3 |
Comparison of PG324 to Ganfort for mean intraocular pressure at specified timepoints at Week 2, Week 6 and Month 3.
| mmHg | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® |
|---|---|---|
| Week 2 | 15.39 (15.09 to 15.84) | 15.56 (15.42 to 15.67) |
| Week 6 | 15.64 (15.18 to 16.20) | 15.25 (15.16 to 15.32) |
| Month 3 | 15.61 (15.28 to 15.93) | 15.19 (15.09 to 15.27) |
Collected over Adverse events were documented for each participant from the time of signing consent until 30 days after the last dose of Investigational Product. This was a maximum period of approximately 9 months (38 weeks) for participants who completed the full study duration.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Netarsudil/Latanoprost 0.02%/0.005% | 0/218 (0%) | 7/218 (3.2%) | 117/218 (53.7%) |
| GANFORT® | 1/212 (0.5%) | 7/212 (3.3%) | 53/212 (25%) |
| Event | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® |
|---|---|---|
| CholecystitisHepatobiliary disorders | 2/218 | 0/212 |
| Accidental poisoningInjury, poisoning and procedural complications | 0/218 | 1/212 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/218 | 1/212 |
| Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/218 | 1/212 |
| Facial paralysisNervous system disorders | 0/218 | 1/212 |
| Ischemic strokeNervous system disorders | 0/218 | 1/212 |
| Cardiac failureCardiac disorders | 0/218 | 1/212 |
| Dermoid cystCongenital, familial and genetic disorders | 0/218 | 1/212 |
| Lower respiratory tract infectionInfections and infestations | 0/218 | 1/212 |
| PneumoniaInfections and infestations | 0/218 | 1/212 |
| Event | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® |
|---|---|---|
| Conjunctival HyperemiaEye disorders | 72/218 | 23/212 |
| Cornea VerticillataEye disorders | 24/218 | 0/212 |
| Conjunctival HemorrhageEye disorders | 18/218 | 5/212 |
| HypertensionVascular disorders | 10/218 | 17/212 |
| Eye PruritusEye disorders | 17/218 | 4/212 |
| Punctate KeratitisEye disorders | 12/218 | 5/212 |
| Conjunctivitis AllergicEye disorders | 12/218 | 1/212 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 11/218 | 10/212 |
436 participants were randomized; 220 to the Netarsudil/Latanoprost 0.02%/0.005% arm and 216 to the Ganfort arm. From the total 436 participants, 6 were not included in the analysis due to serious GCP breaches (see Pre-Assignment Details for more information).
| Age, Categorical(Participants) | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 71 | 79 | 150 |
| >=65 years | 147 | 133 | 280 |
| Age, Continuous(years) | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® | Total |
|---|---|---|---|
| Mean | 67.3 (25 to 91) | 67.0 (22 to 91) | 67.2 (22 to 91) |
| Sex: Female, Male(Participants) | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® | Total |
|---|---|---|---|
| Female | 131 | 92 | 223 |
| Male | 87 | 120 | 207 |
| Ethnicity (NIH/OMB)(Participants) | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® | Total |
|---|---|---|---|
| Hispanic or Latino | 61 | 56 | 117 |
| Not Hispanic or Latino | 157 | 156 | 313 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 9 |
| White | 210 | 200 | 410 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 4 | 8 |
| Region of Enrollment(participants) | Netarsudil/Latanoprost 0.02%/0.005% | GANFORT® | Total |
|---|---|---|---|
| Austria | 17 | 17 | 34 |
| Latvia | 8 | 8 | 16 |
| Belgium | 5 | 5 | 10 |
| Hungary | 8 | 11 | 19 |
| Czechia | 30 | 31 | 61 |
| Poland | 3 | 3 | 6 |
| Italy | 21 | 21 | 42 |
| United Kingdom | 20 | 15 | 35 |
| France | 2 | 4 | 6 |
| Germany | 38 | 36 | 74 |
| Spain | 66 | 61 | 127 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2017 to primary completion in Nov 2020, 38 months.
Results were first posted in Jan 2022, 1 year 2 months after primary completion.
Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 38 months is above that.
Counting every sponsor, half of 49 studies reached it within 25 months; a quarter within 12 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.